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Abstract
The objective of this project was to study the function of O-glycosylations in von Willebrand factor (VWF) life cycle. In total,
14 different murine Vwf cDNAs mutated on one or several O-glycosylations sites were generated: 9 individual mutants, 2
doublets, 2 clusters and 1 mutant with all 9 murine glycosylation sites mutated (Del-O-Gly). We expressed each mutated
cDNA in VWF deficient-mice by hydrodynamic injection. An immunosorbent assay with Peanut Agglutinin (PNA) was used
to verify the O-glycosylation status. Wild-type (WT) VWF expressed by hepatocytes after hydrodynamic injection was able to
bind PNA with slightly higher affinity than endothelial-derived VWF. In contrast, the Del-O-Gly VWF mutant did not bind
PNA, demonstrating removal of O-linked glycans. All mutants displayed a normal multimeric pattern. Two mutants, Del-O-
Gly and T1255A/T1256A, led to expression levels 50% lower than those induced by WT VWF and their half-life in vivo was
significantly reduced. When testing the capacity of each mutant to correct the bleeding time of VWF-deficient mice, we
found that S1486A, T1255A, T1256A and the doublet T1255A/T1256A were unable to do so. In conclusion we have shown
that O-glycosylations are dispensable for normal VWF multimerization and biosynthesis. It also appears that some O-
glycosylation sites, particularly the T1255 and T1256 residues, are involved in the maintenance of VWF plasma levels and are
essential for normal haemostasis. As for the S1486 residue, it seems to be important for platelet binding as demonstrated in
vitro using perfusion experiments.
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Introduction
Von Willebrand Factor (VWF) is a large multimeric plasma
glycoprotein essential for normal haemostasis. Its main role is to
mediate platelet adhesion to exposed subendothelial tissues at sites
of vascular injury [1], and its accessory role is to act as a carrier
molecule for procoagulant factor VIII, thereby protecting it from
premature clearance [2].
During its synthesis which takes place exclusively in megakar-
yocytes and endothelial cells, VWF undergoes extensive post-
translational modifications such as dimerisation, removal of the
propeptide, multimerization and addition of polysaccharidic
chains [3]. There are 12 N-linked and 10 O-linked glycosylation
sites per mature monomer [4]. In VWF, these carbohydrates
account for approximately 20% of the molecular weight of the
protein.
Polysaccharidic chains have been shown to contribute to
a number of cellular processes such as protein folding, stability
and secretion but they can also influence the biological activity and
survival of the molecule [5,6,7].
For VWF, the influence of glycans in its life cycle has long been
known. Indeed it has been reported in 1986 that inhibition of the
attachment of the precursor N-glycan structure to the protein
backbone results in a complete inhibition of initial dimerization of
VWF protomers and subsequent targeting to the Golgi [8]. A
recent article specifically identified four glycosylation sites (one in
the propeptide and three in the mature subunit) involved in this
process [9]. N-glycans are also known to carry ABO blood group
determinants, thus directly influencing VWF levels which are 25%
lower in people with blood group O compared to non-O, due to
an accelerated clearance [10]. Another recently described role for
N-glycosylation in VWF relates to its potential to modulate VWF
interaction with ADAMTS13 and subsequent proteolysis [11].
Although there is ample evidence for the influence of N-
glycosylation in VWF biology and function, it is much less clear for
O-glycosylation. O-linked glycosylation is characterized by the
addition of N-acetyl-galactosamine (GalNAc) to a serine or
a threonine residue followed by other carbohydrates such as
galactose and sialic acid. In human VWF, the predominant O-
linked glycan consists of the sialylated Gal-(b1–3)-GalNAc (also
known as T-antigen) which represents 70–90% of all O-linked
glycan structures. A recent study on the O-glycome of VWF
revealed that a small portion of the O-linked carbohydrates is
characterized by the presence of ABO blood group structures [12].
A few years ago, we have reported that O-linked glycans could
contribute to the regulation of VWF plasma levels since an inverse
correlation was found between the amount of sialylated T-antigen
and plasma levels of VWF [13]. An important aspect of O-linked
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carries the platelet binding site. Indeed, eight out of the ten O-
glycosylation sites of VWF are surrounding this domain. This
observation prompted some investigators to study their influence
on VWF-platelet interaction. In 1992, by producing recombinant
VWF in Chinese Hamster Ovary (CHO) cells allowing selective
suppression of O-linked glycosylations, Carew et al suggested that
these structures were important for optimal binding of VWF to
platelet glycoprotein (GP) Ib in the presence of ristocetin [14]. In
2005, another study using a number of isolated recombinant A1
domains carrying mutations at O-glycosylation sites, reported
either enhanced or decreased platelet interaction according to the
mutation examined [15].
In view of these few and inconclusive studies, we undertook the
characterization of the functional role of VWF O-glycosylation
sites in an in vivo model. Mutations were introduced to abolish O-
glycosylations at specific sites in murine Vwf cDNA and the
different mutants were expressed in VWF-deficient mice by
hydrodynamic injection.
Methods
Ethics statement
The animal facility as well as the protocols used throughout the
study were validated by the Veterinary services under the French
Minister of Agriculture authority. Our official agreement number
is B94-043-13.
Mice
Approximately eight week-old VWF-deficient (VWF
2/2) mice
on a C57BL/6 background bred in the INSERM U770 animal
facility, were used throughout this study. Housing and experiments
were done as recommended by French regulations and the
experimental guidelines of the European Community.
Hydrodynamic injection of plasmid DNA
Plasmid DNA (100 mg or quantities indicated in individual
experiments) diluted in a volume of saline (0.9%) equivalent to
10% of the bodyweight were injected into the mouse tail vein
within 5 seconds. A 2 ml syringe with a 26
K gauge needle was
used.
Selection and construction of O-glycosylation mVWF
mutants
O-linked glycosylation sites on human VWF were identified in
1986 by Titani et al [4]. Experimental evidence was based on the
lack of identifiable phenylthiohydantoins after Edman degradation
at known threonine/serine sites, associated with the presence of
proline residues in the vicinity. No such studies have been
performed with murine VWF (mVWF) and therefore the presence
of O-linked glycosylations at conserved sites can be questioned. Of
the 10 threonine/serine residues reported to carry O-glycosylation
on human VWF cDNA, 9 are conserved in mVwf cDNA (Table 1).
We first used an internet-server-based neuronal network for
prediction of mucin type GalNac O-glycosylation sites in
mammalian proteins (http://www.cbs.dtu.dk/services/
NetOGlyc-3.0/). However, using human VWF primary sequence
as a test sequence, we did not get satisfying results since only 5 out
of the 10 sites identified by Titani et al were predicted to be O-
glycosylated and one additional site, not identified by Titani, was
considered a putative site for O-glycosylation using the online tool.
We therefore decided to make the assumption that when the
threonine/serine residue was conserved between human and
mouse, we would consider that this residue was O-glycosylated.
This assumption is based on the fact that there is normally very
little evolutionary pressure to conserve site-specific mucin-type
glycosylated serines and threonines [16]. So the observation that
residues predicted to be O-glycosylated in the human VWF
sequence are very well conserved in sequences of different species
(see Table 1) would argue in favor of a specific role of these
residues and therefore would justify their conserved O-glycosyl-
ation status.
Full-length murine Vwf (mVwf) wild-type (WT) cDNA inserted
into a pLIVE expression vector (Mirus Bio, Madison, WI) was
used as template for the introduction of mutations [17]. 14
mutants were generated: 9 single mutants, 2 double mutants
(T1255A/T1256A and S1486A/S1487A), 2 clusters surrounding
the A1 domain (T1248A/T1255A/T1256A and T1468A/
T1477A/S1486A/S1487A) and 1 mutant deleted of all 9 O-
glycosylation sites (Del-O-Gly). Mutant Del-O-Gly was con-
structed in three subsequent steps. First, a fragment containing
mutations T1468A/T1477A/S1486A/S1487A (cluster 2) was
ligated into the cDNA containing the mutations T1248A/
T1255A/T1256A (cluster 1). This cluster 1/cluster 2 construct
was then used as a template to incorporate the T1679A mutation.
Finally, the cluster 1/cluster 2/T1679A construct was used as
a template to introduce the T2298A mutation. WT, T1255A/
T1256A and Del-O-Gly mVwf cDNAs were also subcloned in the
pNUT vector for transfection of COS-7 cells. pNUT is an
expression plasmid described previously [18].
Two different techniques of site-directed mutagenesis were used
for generation of the mutants, overlap extension using the
polymerase chain reaction or QuikChange II XL Site-Directed
Mutagenesis Kit (Stratagene, Agilent Technologies France, Massy,
France). All Serine or Threonine residues were mutated in Alanine
and the primers used for the mutations are summarized in table 2.
To check for the absence of undesired mutations all 14 mutants
were entirely sequenced using either the ABI PRISM Dye
Terminator Cycle Sequencing Reaction Kit v3.1 (Applied
Biosystems, Applera, Courtaboeuf, France) on an ABI PRISM
310 DNA sequencer according to the manufacturer’s specifica-
tions or using the Genomics services company COGENICS
(Takeley, Essex, United Kingdom). Plasmid DNA was amplified in
Escherichia coli DH5a cells and purified by a Nucleobond
endotoxin-free plasmid DNA PC 2000 kit (Macherey-Nagel,
Hoerdt, France).
Cell culture and transfection
COS-7 were grown in Dulbecco’s modified eagle medium
(DMEM) with 4.5 g/l glucose containing 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (all from Invitro-
gen, Cergy Pontoise, France) and 10% fetal calf serum (FCS)
(Biowest, Nuaille France). COS-7 were transiently transfected by
electroporation (255 Volts, 1500 mF, ‘ Ohm) using 10 mgo f
a pNUT expression vector containing mVwf cDNA either WT or
mutated (T1255A/T1256A or Del-O-Gly). Transfected COS-7
cells were incubated for 24 hours in MCDB medium (Sigma, Saint
Quentin Fallavier, France) with 10% FCS. Then, the medium was
changed to serum-free MCDB medium and harvested after
72 hours. Protease inhibitors (1 mM benzamidine, 0.5 mM 4-2-
aminoethyl-bezensulfonylfluoride-HCl and 1 mM N-ethylmalei-
mide) were added to the culture media and the mix was
centrifuged for 20 minutes at 4,000 g to remove cells debris.
Transfected COS-7 cells were washed twice in PBS and lysed after
5 minutes incubation at room temperature with 1.5 ml lysis buffer
(10 mM Tris-HCL pH 8.0, 150 mM NaCl, 5 mM EDTA, 1%
Nonidet P-40) containing protease inhibitors. Culture medium and
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subsequent analysis.
Bleeding time assay
Four to five days after hydrodynamic injection, mice were
anesthetized with tribromoethanol 2.5% (0.15 ml per 10 g of body
weight) and 3 mm of the distal tail were cut using a scapel. The
amputated tail was immersed immediately in a 50 ml tube
containing physiologic saline at 37uC. Bleeding time was measured
from the moment of transection until first arrest of bleeding.
Observation was stopped at 600 seconds when bleeding did not
cease. VWF expression levels were determined in all mice, and
only those expressing 300–1000% were included in this analysis.
Blood collection and determination of murine VWF
antigen levels by enzyme-linked immunosorbent assay
Mice were anesthetized with tribromoethanol 2.5%, and blood
was collected from the retroorbital venous plexus into plastic tubes
containing trisodium citrate 1.138M (9:1, v:v). To obtain platelet-
poor plasma, blood samples were centrifuged at 1500 g for
20 minutes at 22uC. Plasma VWF concentration was measured
according to a previously described immunosorbent assay using
a polyclonal antibody anti-human VWF (Dako France SAS,
Trappes, France) and a horseradish peroxidase-conjugated poly-
clonal antibody anti-human VWF (Dako) [19]. These polyclonal
anti-human VWF antibodies cross-react with murine VWF and
can be used for the analysis of murine VWF plasma levels [20].
Normal pooled plasma from 20 C57BL/6 WT mice was used as
reference and set at 100%. Results were expressed as a percentage
of normal murine VWF level.
VWF multimer structure analysis
The multimeric structure of VWF was analysed by 0.1%
sodium dodecyl sulfate (SDS) and 2% agarose (GE Healthcare,
Velizy, France) gel electrophoresis [21]. Multimers were visualized
using an alkaline phosphatase-conjugated anti-human VWF
polyclonal antibody.
Clearance of VWF
Four days after hydrodynamic injection of VWF-deficient mice
with selected O-glycosylation mutants, mice were injected in-
travenously within the tail vein with 500 mg of biotin-N-
hydroxysuccinimide ester (NHS, Calbiochem, Merck Chemicals
Ltd, Nottingham, United Kingdom) dissolved in saline buffer [17].
The biotinylation reaction was allowed to complete for 10 min
and blood was collected (100 ml), corresponding to time=0.
Additional collections were performed at 0.5, 1, 2, 6 and 24 hours
after t=0. Three mice were used for each time point. Residual
biotinylated VWF was measured by an immunosorbent assay,
using polyclonal anti-human VWF antibodies (Dako) and horse-
radish peroxidase-labeled streptavidin (R&D Systems Europe,
Lille, France) and was expressed as the percentage of biotinylated
VWF levels at t=0. For each mouse, samples taken at t=0 were
set at 100%, which served as a reference for later time points. Data
were fitted with the use of GraphPad Prism (Version 5 for Mac
OSX; GraphPad Software).
Immunosorbent assay for VWF-linked T antigen to detect
O-linked sugars on VWF
96 wells plates (Greiner Bio-One SAS, Courtaboeuf, France)
were coated with polyclonal anti-VWF antibodies 3 mg/ml (Dako)
for 2 hours at 37uC and post-coated 1 hour at 37uC with PBS/
BSA 3%. Wells were washed 3 times with PBS/0.1%Tween-20
(PBS/T) and incubated 3 hours at 37uC with dilutions of plasma
samples from mice injected hydrodynamically with selected O-
linked glycosylation mutants. A preliminary step to measure VWF
expression level had been performed in order to adjust antigen
concentration to 100% in all plasma samples. After washing 3
times with PBS/T, wells were incubated with 5 mU/ml
neuraminidase (Roche Diagnostics, Meylan, France) in PBS/
1 mM CaCl2 overnight at 37uC. After 3 washes with PBS/T, non-
specific binding sites were then blocked with the avidin/biotin
blocking kit (Vector Laboratories, Burlingame, CA) according to
the manufacturer’s instructions. After washing 3 times with PBS/
0.1%Tween-20, biotinylated peanut agglutinin (btPNA) (Vector
Laboratories) in PBS/0.1 mM CaCl2 was added for 2 hours at
37uC. Finally, wells were incubated with HRP conjugated
streptavidin. Bound btPNA was detected by measuring HRP
activity using OPD as substrate [13]. A similar experimental
approach in which the de-sialylation step was omitted was also
used to test binding of two other biotinylated lectins, Erythrina
Cristagalli (ECL, which recognizes terminal Galactose) and Wheat
Germ Agglutinin (WGA, which recognizes terminal N-acetylglu-
cosamine and sialic acids). Both lectins were obtained from Vector
Laboratories.
Table 1. Conservation of residues known to carry O-glycosylations on human VWF in a number of animal species.
Human T1248 T1255 T1256 S1263 T1468 T1477 S1486 T1487 T1679 T2298
Mouse - - - P1263 ---S1487 --
Rat - - - P1263 ---S1487 --
Cow - - - P1263 ---L1487 - S2298
Rabbit - - I1256 E1263 ---P1487 --
Cat - - - P1263 ---S1487 --
Dog - - - P1263 ---S1487 --
Horse - - I1256 P1263 ---P1487 --
Chimpanzee - - ------- -
Boar - - - P1263 ----- -
Pig - - - P1263 ----- -
In bold are residues that are not conserved and in italics are residues that are modified but could still carry O-glycosylations (change of a threonine to serine). Residues
are conserved when nothing is indicated.
doi:10.1371/journal.pone.0037508.t001
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Blood perfusion experiments were performed in a parallel plate
perfusion chamber essentially as described previously [22].
PPACK (80 mM) anticoagulated blood from VWF-expressing
mice was incubated with rhodamine 6G (10 mg/ml) for 5 min at
37uC and then perfused on glass coverslips pre-coated overnight at
4uC with fibrillar equine type 1 collagen (100 mg/ml) at a shear
rate of 2500 s
21 with a syringe pump (Fisher Scientific, Ottawa,
Canada) for 1 min. Unbound material was removed by a sub-
sequent perfusion with Hepes-Tyrode buffer for 30 sec. Thrombus
formation was recorded with an inverted epifluorescence micro-
scope (Nikon Eclipse TE2000-U) coupled to the Metamorph-7.0rl
software (Universal Imaging Corporation) and was quantified by
the assessment of the mean percentage of the total area covered by
platelets using ImageJ-1.44 software (http://rsbweb.nih.gov/ij/
index.html).
Results
Detection of O-linked sugars on VWF expressed in mice
after hydrodynamic injection
In VWF, the predominant O-linked glycan consists of the
sialylated T-antigen [23]. A few years ago, we developed a specific
assay using btPNA, a lectin that specifically recognizes the non-
sialylated T-antigen and we were able to measure the amount of
O-linked sugars on VWF in various plasma samples from patients
[13]. In the present study we first adapted the test for murine
plasma samples. Then, considering that VWF produced after
hydrodynamic injection is synthesized by hepatocytes and not by
endothelial cells or megakaryocytes, we wanted to check whether
similar glycosylation structures were present on the molecule. We
first used the btPNA assay to compare normal pooled plasma from
WT mice to plasma samples from VWF-deficient mice injected
hydrodynamically with WT-mVwf cDNA. As shown in Fig. 1A,
btPNA bound more avidly to WT-VWF from plasma of mice after
hydrodynamic injection (Half-maximum binding 3.260.4 mg/ml
and 0.560.1 mg/ml for normal pooled plasma and WT-VWF,
respectively; p,0.0001), potentially suggesting a better access of
the lectin to the O-linked glycans in this setting. However, the
similar Bmax value indicated that an equivalent number of
binding sites were present in both samples. As a negative control,
plasma from a VWF-deficient mouse was tested and no binding to
btPNA could be observed. In addition, no btPNA binding was
observed to mice expressing the Del-O-Gly variant in which all 9
potential O-linked glycosylation sites were mutated. This suggests,
that besides the 9 O-linked sites, no additional glycosylation sites
are present that contain the Gal-(b1–3)-GalNAc structure. In
a second series of controls, we also examined the binding of lectins
ECL and WGA, which recognize terminal galactose and sialic
acids, respectively. Both lectins bound efficiently to VWF from
normal C57Bl6 mice (Figs. 1B and 1C, respectively). Efficient
binding was also observed for WT-VWF from plasma of mice after
hydrodynamic injection, with both Bmax and half-maximal
binding being similar to those of normal VWF. Apparently,
a similar extent of terminal galactose and sialic acids are exposed
on endothelial- and hepatic-derived VWF.
Multimeric analysis of O-glycosylation mutants
In order to study the potential role of O-linked glycosylation on
VWF multimerization, we loaded plasma samples from VWF-
deficient mice injected with WT or mutated mVwf cDNA on 2%
agarose gel. Fig. 2 shows the profile obtained with all 14 mutants
as compared to WT cDNA. Faster migration is visible for the Del-
O-Gly and also for the Cluster 2 mutant, demonstrating that we
have indeed removed glycosylations normally contributing to the
molecular mass of VWF. All mutants, including the Del-O-Gly
construct led to the production of multimers covering the entire
range of molecular weight. This was confirmed via densitometric
analysis of 2 (for 6 mutants) or 3 (for 8 mutants) independent
multimer patterns. For WT, we analyzed 7 independent multimer
patterns. Multimer distribution for WT was as follows: 1–5
multimers: 7164% of total multimers, 6–10 multimers: 2264%,
11–15 multimers: 661%, .15 multimers: 1.060.4%. A similar
distribution was found for all mutants (1-way ANOVA: p.0.05 for
each of the multimer ranges).
VWF expression levels after hydrodynamic injection of O-
glycosylation mutants in VWF-deficient mice
To investigate the consequences on VWF expression levels of
removing one or more O-linked glycosylation sites, we injected all
14 mutants in VWF-deficient mice by hydrodynamic injection
(100 mg of cDNA) and we measured VWF antigen 4 to 5 days
after the injection. We previously showed that the technique using
the pLIVE vector allows a stable expression for at least two weeks
[24]. All mutants were compared to WT mVwf cDNA, which is
expressed at a mean level of 833676%. As shown in Fig. 3, 12 out
of 14 mutants were expressed at levels very close to the WT, not
showing any statistical differences. In contrast, two mutants led
repeatedly to lower expression levels: the T1255A/T1256A
Table 2. List of primers used for generation of O-linked
glycosylation mutants.
PRIMERS NAMES NUCLEOTIDE SEQUENCES
T1248AVWFmuS 59GCCTGGTCGCCCCCCCCGCAGATGCCCCAGTCAGC 39
T1248AVWFmuAS 59GCTGACTGGGGCATCTGCGGGGGGGGCGACCAGGC 39
T1255AVWFmuS 59GTCAGCTCTGCCACCCCATATGTT 39
T1255AVWFmuAS 59AACATATGGGGTGGCAGAGCTGAC 39
T1256AVWFmuS 59GTCAGCTCTGCCACCCCATATGTT 39
T1256AVWFmuAS 59AACATATGGGGCGGTAGAGCTGAC 39
T1468AVWFmuS 59GCCCCAGCCCCAGCTCAGCCTCCACAG 39
T1468AVWFmuAS 59CTGTGGAGGCTGAGCTGGGGCTGGGGC 39
T1477AVWFmuS 59GTAGCCCATGTCGCCGTGAGTCCAGGG 39
T1477AVWFmuAS 59CCCTGGACTCACGGCGACATGGGCTAC 39
S1486AVWFmuS 59GCTGGGATCGCGTCACCGGGACCA 39
S1486AVWFmuAS 59TGGTCCCGGTGACGCGATCCCAGC 39
S1487AVWFmuS 59GCTGGGATCTCGGCACCGGGACCA 39
S1487AVWFmuAS 59TGGTCCCGGTGCCGAGATCCCAGC 39
T1679AVWFmuS 59CAACTGCCCGCCCTCCCCCCTCTC 39
T1679VWFmuAS 59GAGAGGGGGGAGGGCGGGCAGTTG 39
T2298AVWFmuS 59CCGTGTCCCGCAGCCCGAGCTCCC 39
T2298AVWFmuAS 59GGGAGCTCGGGCTGCGGGACACGG 39
T1255–
T1256AVWFmuS
59GTCAGCTCTGCCGCCCCATATGTT 39
T1255–
T1256VWFmuAS
59AACATATGGGGCGGCAGAGCTGAC 39
S1486–
S1487VWFmuS
59GCTGGGATCGCGGCACCGGGACCACAG 39
S1486–
S1487VWFmuAS
59CTGTGGTCCCGGTGCCGCGATCCCAGC 39
Mutated nucleotides are written in bold.
doi:10.1371/journal.pone.0037508.t002
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Del-O-Gly mutant with complete removal of all 9 O-linked
glycosylation sites (435680%, p,0.05 as compared to WT
cDNA).
Cellular transfection of mutants with low expression
levels
To investigate if lower synthesis could contribute to the low
expression levels obtained with the T1255A/T1256A and Del-O-
Gly mutants, we performed transient transfections in COS-7 cells
with these two mutants and WT mVwf. After transfection by
electroporation, VWF antigen levels were measured in both the
cell lysate and the supernatant (Fig. 4A). We observed lower VWF
expression in the cell supernatant of the Del-O-Gly mutant
compared to WT (p=0.022). However, no intracellular retention
could be detected. For the T1255A/T1256A mutant, no
difference in cell supernatant or cell lysate was measured
compared to WT (p=0.12 for the supernatant).
Clearance of O-linked glycosylation mutants in mice
We also investigated whether the low expression levels in the
T1255A/T1256A or the Del-O-Gly mutants could result from
increased clearance. mVwf cDNA (WT or mutant) were injected
via hydrodynamic injection in VWF-deficient mice. Four days
later, mice were injected with NHS-biotin to label circulating
VWF. Subsequently, samples were taken at indicated time points
and residual biotinylated VWF in plasma was determined.
Elimination of WT-mVWF from the circulation followed a single
exponential decay with a calculated half-life of 6.161 hour (95%
confidence interval [CI], 4.2–10.9 hours; Fig. 4B). A single-
exponential decay was also observed for both mutants. However,
half-life was significantly shorter for both mutants compared to
WT-mVWF (p=0.0011): 3.060.3 hours (95% CI, 2.4–4.2 hours)
for the T1255A/T1256A mutant and 2.960.2 hours (95% CI,
2.5–3.4 hours) for the Del-O-Gly mutant (Fig. 4B).
Effect of O-glycosylation mutations on bleeding time
To evaluate the importance of O-glycosylations on VWF
function, we compared the ability of each mutant to correct
bleeding time in VWF-deficient mice. In this model, injection of
WT-mVwf cDNA leads to bleeding time correction [24,25]. In
contrast, injection of an empty pLIVE-plasmid leaves the bleeding
tendency unaffected, with no arrest of bleeding during the 10-min
observation period. Among the 9 single mutants, three appeared
significantly different from the WT-VWF, with the majority of the
mice showing a prolonged bleeding time: T1255A (p=0.045 vs
WT), T1256A (p=0.048 vs WT) and S1486A (p=0.03 vs WT)
(Fig. 5). When both adjacent residues were mutated (T1255A/
T1256A), none of the mice were able to stop bleeding (p,0.001 vs
WT). This result was independent of the lower expression levels
obtained with this particular mutant. Indeed for the bleeding time
experiment we only kept mice expressing VWF:Ag levels between
300 and 1000%, a range where bleeding time correction is
systematically obtained with WT-VWF. Interestingly, mutating
the residues 1255 and 1256 together with additional O-glycosyla-
tions sites, such as the Del-O-Gly or the cluster 1 where residue
1248 is also mutated, abolished the effect observed with the double
mutant (Fig. 5). Similarly, mutating S1486A together with its
adjacent residue, S1487A or in the context of the cluster 2 or in
the Del-O-Gly also abolished the decreased functionality observed
with this particular mutant.
Figure 1. Detection of T antigen on VWF in murine plasma.
Microtiter wells coated with polyclonal anti-VWF antibodies (3 mg/ml)
were incubated with serial dilutions of murine plasma previously
adjusted for VWF concentration. After catching VWF, wells were
incubated with neuraminidase (5 mU/ml) in PBS/1 mM CaCl2 overnight
at 37uC (neuraminidase incubation was omitted for data presented in
panels B and C). Subsequently, wells were blocked with the avidin/
biotin blocking kit and incubated for 2 hours at 37uC with btPNA (panel
A), btECL (panel B) or btWGA (panel C). After washing, HRP-conjugated
streptavidin was added to the wells and bound lectin was detected by
measuring HRP activity using OPD as a substrate. Panel A: btPNA
binding to pooled plasma of C57Bl6J mice (Pool), plasma of WT-VWF
expressing mice (WT), plasma of Del-O-Gly expressing mice (Del-O-Gly)
and plasma of VWF-deficient mice (VWF2/2); Panel B: btECL binding to
Pool and WT; Panel C: btWGA binding to Pool and WT. Plotted is the
relative response (% of maximum binding) versus concentration of VWF
in diluted samples. The relative response is defined as binding being
relative to binding of the lectins to WT VWF (5 mg/ml for btPNA and
0.125 mg/ml for btECL and btWGA), which was arbitrarily set at 100%.
Data points represent the mean6SD of 3–6 measurements.
doi:10.1371/journal.pone.0037508.g001
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The reduced haemostatic capacity of the mutants associated
with a prolonged bleeding time (i.e. T1255A, T1256A, T1255A/
T1256A and S1486A) was further investigated in a perfusion
system in which blood of mice expressing WT or mutant VWF was
perfused over a collagen surface at a flow rate of 2500 s
21. At such
flow rates, adhesion of platelets to collagen is dominated by the
action of VWF. Efficient platelet adhesion to collagen was
observed when blood of WT-VWF expressing mice was perfused,
and platelet-rich thrombi developed homogeneously dispersed
over the collagen surface. Platelet surface coverage was calculated
to be 15.860.9% (mean6SEM; Fig. 6). When blood of VWF
2/2
mice that were treated with an empty pLIVE plasmid was
perfused under identical conditions, a reduction in the number of
adhered platelets was observed and few thrombi developed (Fig. 6).
Reduced thrombus formation in the complete absence of VWF
was corresponding to a significantly reduced platelet surface
coverage: 6.261.2% (p,0.0001). Interestingly, platelet surface
coverage was also reduced for each of the mutants tested: T1255A:
8.261.2%; T1256A: 6.461.2%, T1255A/T1256A: 6.060.9%;
p,0.001 for all three mutants; S1486A: 11.661.0%, p=0.006
(Fig. 6). Qualitatively, we observed that all mutants are charac-
terized by the presence of small under-developed thrombi, with
few larger thrombi (if any for mutants T1256A and the double
mutant). Taken together, the reduced haemostatic capacity of
these mutants seems to originate predominantly from a reduced
potential to build a thrombus under conditions of arterial shear.
Discussion
The contribution of O-linked glycans to the properties of
glycoproteins is not always well understood and in the particular
case of VWF, only very few studies are available in this regard.
This lack of information on the role of these carbohydrates in the
regulation and function of VWF prompted us to initiate the
present study aiming to characterize their contribution in an in vivo
model. Considering the large number of O-glycosylation sites
present on human VWF, we chose the hydrodynamic injection
technique to express the different mutants in vivo [17,24,25].
Indeed, such an approach allowed us to study all individual
mutants as well as combinations thereof in VWF-deficient mice. In
order to assess functionality, mutagenesis was performed on
murine VWF. Out of the 10 O-glycosylation sites present on
human VWF, 9 are conserved in the mouse sequence [26] and all
9 were individually replaced by an alanine. Two clusters of 3 and 4
mutations respectively, were also generated as well as two doublets
and one mutant with all 9 mutations (Del-O-Gly). VWF-deficient
mice were injected with the various mVwf cDNAs and experiments
were performed 4–6 days following injection, a time window in
which expression levels are stable as we previously showed [24].
Our approach raised two main difficulties. The first one, inherent
Figure 2. Multimeric analysis of O-glycosylation mutants. VWF-deficient mice were injected with 100 mg of pLIVE-mVwf, WT or the various O-
glycosylation mutants. Plasma was collected 96 hours later and analysis of plasma samples was performed by SDS/2% agarose gel electrophoresis.
doi:10.1371/journal.pone.0037508.g002
Figure 3. VWF:Ag expression levels following hydrodynamic
gene delivery. VWF-deficient mice were injected with 100 mgo f
pLIVE-mVwf, WT or the various O-glycosylation mutants. Plasma was
collected 96 hours later and VWF:Ag levels were measured by ELISA.
Data are represented as mean plus or minus SEM. Normal pooled
plasma from 20 C57BL/6 mice was used as a reference and set at 100%.
Results are expressed as a percentage of a normal murine level. n=22
for WT cDNA and 4–5 for the various mutants. * p,0.05 calculated with
unpaired t-test when comparing the mutant with WT cDNA.
doi:10.1371/journal.pone.0037508.g003
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glycosylation profile of a protein not produced by its original
parental cell, which may cause subtle differences in this profile.
Unfortunately, with the current technologies available it is not
realistic to study the structural and functional consequences of 14
mutations in vivo via endothelial-specific expression of these
mutants. So far, studies on the analysis of glycosylation mutants of
human VWF have been based on the expression of VWF in
heterologous expression systems using CHO- or HEK293-cells
[9,14,27]. In none of these cells the glycosylation profile of the
protein is similar that that found in endothelial-derived VWF.
Nevertheless, valuable information was obtained in these studies
despite the limitations of the model, indicating that the use of
heterologous expression systems is useful in the study of VWF
glycosylation. In our system, VWF is produced as a functional
multimerized protein. Binding of the lectins ECL (recognizing
terminal galactose residues) and WGA (recognizing terminal N-
acetylglucosamine and N-acetylneuraminic acid) was similar for
both endothelial- and hepatic-derived VWF, indicating that the
overall N- and O-linked glycosylation pattern is not dramatically
different between both proteins. Moreover, these data indicate
that the hepatic-derived VWF is properly sialylated. Indeed,
a reduced extent of sialylation would be associated with increased
ECL- and decreased WGA-binding. Of course, subtle differences
in N-linked glycosylation are not detected using this lectin-based
approach and additional studies using mass spectrometrical
analysis would be needed in this regard.
As for the O-linked glycans, it is known that recombinant VWF
produced in CHO cells as well as plasma-derived VWF contains as
the predominant O-linked glycan, a sialylated Gal-(b1–3)-GalNAc
structure, representing 70–90% of all O-linked glycan structures
[12,23,28]. Here we show, using a specific PNA-lectin assay to
measure the presence of this Gal-(b1–3)-GalNAc structure, that
hepatocyte-derived VWF is not fundamentally different from
endothelial-derived VWF in terms of PNA recognition (Fig. 1A).
Bmax values indicated very similar number of binding sites for
VWF of both origins. In addition, no btPNA binding to Del-O-Gly
mutant was detected, suggesting that no additional btPNA
Figure 4. Cellular expression and in vivo clearance of O-glycosylation mutants. Panel A: pNUT vectors containing WT-mVwf cDNA, T1255A/
T1256A or the Del-O-Gly mutant were transfected in COS-7 cells by electroporation. 96 hours later, cell supernatants were collected and cells were
lysed. VWF antigen levels were measured by ELISA in the supernatants (grey bars) and lysates (white bars) for each mutant and the WT mVWF. n=7–8
individual transfections, * p=0.022 using unpaired t-test when comparing to WT. Panel B: After injection with NHS-biotin, residual biotinylated VWF
was determined at indicated time points. Data present the percentage of residual biotinylated VWF measured at t=0, which was set at 100% for each
mouse. Curves indicate the best fit for an exponential decay.
doi:10.1371/journal.pone.0037508.g004
Figure 5. Effect of O-glycosylation mutations on bleeding time. VWF-deficient mice were injected with pLIVE-mVwf, WT or the various O-
glycosylation mutants. In order to reach VWF:Ag expression levels between 300 and 1000%, 100 mg of cDNA was used for WT and most mutants
while 150 mg was used for T1255A/T1256A or Del-O-Gly. Four to five days after injection, mice were anesthetized and 3 mm of the tail were cut. The
amputated tail was immersed immediately in a 50 ml tube containing physiologic saline at 37uC. Bleeding time was measured from the moment of
transection until first arrest of bleeding. Observation was stopped at 600 seconds when bleeding did not cease. *: p,0.05 using unpaired t-test when
comparing mutant T1255A or T1256A to WT. **: p=0.03 using unpaired t-test when comparing mutant S1486A to WT. ***: p,0.0001 using unpaired
t-test when comparing mutant T1255A/T1256A to WT.
doi:10.1371/journal.pone.0037508.g005
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sites that we have mutated. Moreover, we could demonstrate the
specificity of the test by the absence of lectin binding to plasma
from VWF-deficient mouse. The only difference we could observe
between endothelial- and hepatic-derived VWF came from
a slightly higher affinity of the lectin for hepatocyte-derived
VWF (Fig. 1). The reason for this higher affinity is not completely
clear. Since potential differences between hepatic- and endothe-
lial-derived VWF are probably limited to the glycan structures, we
anticipate that small differences in surrounding N-linked glycans
may contribute to the higher affinity for PNA. It remains difficult
to predict how the N-linked glycans elsewhere in the VWF protein
are exactly located in comparison to the O-linked glycans in
perspective of a three-dimensional structure. It should be noted
that the D3 and A2 domains adjacent to the A1 domain (which
contains the two O-linked clusters) both contain 2 N-linked
glycans. Given that both the D’D3 region and the A2 domain have
been reported to cover the A1 domain [29,30], it is possible that
changes in these N-linked glycans modulate the access of btPNA to
the O-linked glycans around the A1 domain. This may also be true
for the single O-glycan in the B1–3 domain, which contains 4
additional N-linked glycans. Taken together, we feel that our
model is not less relevant than other heterologous models
[9,14,15,27] to study the effect of glycosylation mutations on
VWF structure and function, despite the potential limitations of
our in vivo model.
Figure 6. Ex vivo thrombus formation on collagen. Panel A: Blood was collected from mice 4 days after hydrodynamic injection with pLIVE
encoding WT VWF or one of the following mutants: T1255A, T1256A, T1255A/T1256A, S1486A. As a control, mice were treated with an empty pLIVE
plasmid (empty pLIVE). Anticoagulated whole blood was incubated with rhodamine 6G to fluorescently label platelets and perfused over collagen-
coated glass coverslips (flow rate 2500 s
21) for a period of 1 min. Unbound platelets were removed by subsequent perfusion with Hepes-Tyrode
buffer. Thrombus formation was then visualized via image acquisition using Metamorph software. Shown are representative images for WT VWF,
each mutant and the negative control (empty pLIVE). Panel B: Thrombus formation was quantified using ImageJ software in order to calculate
percentages of platelet surface coverage. Data represent the mean6SEM of three independent perfusions, with 3–8 images being analyzed for each
perfusion. **: p=0.006 using unpaired t-test when compared to WT. ***: p,0.0001 using unpaired t-test when compared to WT.
doi:10.1371/journal.pone.0037508.g006
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murine VWF for which no experimental data on the position of O-
linked glycosylations, were available. Since online prediction tools
did not appear to be reliable for this protein, we assumed that O-
glycosylations were present on the same residues in humans and in
mice when these residues were conserved. In addition, we assumed
that the majority of the glycans consisted of the sialylated T-
antigen, as has been found for human VWF [12]. The absence of
binding sites for the PNA lectin on the Del-O-Gly variant (Fig. 1)
confirms that apart from the 9 selected mutations no other Ser/
Thr residues are glycosylated with this Gal-(b1–3)-GalNAc
structure, or become so in a compensatory manner. Furthermore,
the faster migration of the Del-O-Gly mutant in multimeric gels
(Fig. 2) is also compatible with the removal of substantial amounts
of glycan structures (molecular weight sialylated T-antigen:
0.7 kDa). Of note, our data do not fully rule the presence of
non-T-antigen structures elsewhere in the molecule, but given the
data on the number of non-T-antigen structures on human VWF
(#1 per subunit) and the loss in molecular mass in Del-O-Gly it
seems that few if any of such structures are present in the Del-O-
Gly variant. Taken together, in view of all these validation steps we
felt confident that our model was pertinent to investigate structure
and function of O-linked glycan mutants in vivo.
First we checked the contribution of O-linked glycans to VWF
multimerization. All 14 mutants, including the Del-O-Gly, were
able to multimerize (Fig. 2), suggesting that O-linked glycans are
dispensable for this essential step in VWF life-cycle. This result is
in accordance with a previous study where recombinant VWF was
produced in a cell line with a carbohydrate defect, resulting in the
production of fully multimerized VWF specifically lacking O-
linked carbohydrates [14]. We next investigated the effect of our
mutations on VWF expression levels and found that all mutants
were expressed in the mice (Fig. 3). Apparently, O-glycosylations
are not a prerequisite for VWF biosynthesis and secretion, which is
opposite to the role of some N-glycosylations [8]. Interestingly, two
mutants showed repeatedly a 50% decrease in plasma antigen
levels: the T1255A/T1256A doublet and the Del-O-Gly mutant.
We considered the possibility that reduced antigen levels were
associated with a decreased production efficiency. Indeed expres-
sion of the Del-O-Gly mutant led to slightly reduced levels of VWF
in the extracellular medium compared to WT-VWF using
transient transfection in COS-7 cells (Fig. 4). However, no such
effect was observed for the T1255A/T1256A doublet. In both
cases, the reduced antigen levels following in vivo expression was
not fully explained by defective biosynthesis. An alternative
hypothesis to explain the lower VWF levels in vivo originated
from the possibility that these two forms of VWF could be
removed quicker from the circulation. Indeed, clearance experi-
ments in mice demonstrated that VWF with two mutations in
positions 1255/12566 or with all 9 O-glycosylation sites removed,
was eliminated significantly quicker than WT-VWF, accounting
for the observed lower plasma levels. This finding is in agreement
with our previous study describing a linear relation between PNA
binding and propeptide/VWF ratio in humans, suggesting
a potential association between O-linked glycosylation and VWF
survival [13].
One of the main goals of our study was to investigate the
functionality of VWF mutated at specific O-glycosylation sites.
The clustering of 8 out 10 of theses sites around the A1 domain in
human VWF is particularly intriguing since VWF A1 domain
contains the binding site for platelet GPIb. In an attempt to
understand the relevance of this structural particularity and
therefore the influence of O-linked glycans on platelet binding,
previous studies led to conflicting data. A first report described
a decreased interaction between VWF lacking O-linked glycans
and GPIb when ristocetin was used as a modulator but not when
botrocetin was used, suggesting a potential role of O-linked
glycans in the interaction with ristocetin rather than directly with
GPIb [14]. A second more recent study used a mutagenesis
approach to replace specific glycosylation sites with alanine
residues [15]. However, this study was done on isolated A1
domain encompassing residues 1236–1476, limiting the evaluation
to 4 O-glycosylation sites upstream of the A1 domain and to only 1
site downstream of the A1 domain. The results showed that
mutations in the O-linked glycans located in the amino-terminal
A1 flanking region increased VWF interaction with GPIb while
mutating the 1468 residue in the carboxy-terminal A1 flanking
region had the opposite effect [15]. Many questions remained
unanswered following these two studies, prompting us to evaluate
the capacity of O-glycosylations to regulate VWF function in our
in vivo model. Our results show that mutation of the T1255/T1256
doublet, of T1255, of T1256 and of S1486 led to non-functional
forms of VWF and mice expressing these mutants were unable to
correct their bleeding time (Fig. 5). The prolonged bleeding for the
T1255/T1256 doublet was not due to decreased levels of VWF
antigen in these mice. Like for all other WT and mutants tested,
antigen levels were in the range between 300% and 1000%,
a range where we observe correction of bleeding with WT
systematically. Moreover, expression levels for this double mutant
and the Del-O-Gly were near identical (Fig. 3), with the latter
being associated with fully corrected bleeding times in all mice.
The reduced function of these VWF mutants was confirmed in
separate ex vivo perfusion studies, in which blood of mice expressing
these mutants was perfused over a collagen surface at high shear
rates (flow rate 2500 s
-1). Indeed, all four mutants were associated
with reduced platelet surface coverage under these conditions
(Fig. 6).
But the most surprising result came from the observation that
the cluster mutants and the Del-O-Gly mutant were no different
from WT-VWF in their ability to correct bleeding time in VWF-
deficient mice. Apparently, the detrimental effect of the absence of
a single or doublet glycan structure is rescued by the deletion of
additional glycans or even the complete O-glycome. How to
explain this observation? At this point we can but speculate on the
underlying mechanism, and we would like to share two possible
options with the readers. A first possibility is based on the
assumption that the O-glycans per se do not interact directly with
GpIb. This assumption is compatible with the Del-O-Gly being as
functional as WT VWF as well as with the fact that E. coli-derived
A1 domain fragments lacking glycan structures interact efficiently
with GPIb [31]. Consequently, the effect of selective deleted O-
glycans on GpIb binding is indirect and perhaps related to the
charged nature of the glycans. Clusters of sialylated glycans
represent a highly negatively-charged region. Selective removal of
one or several of these negatively-charged glycans from these
clusters may cause a profound charge-dependent re-orientation of
the region, which could modulate the interaction with GPIb. Such
effects would then be neutralized by the removal of additional
glycan structures. A second possibility is based on the assumption
that the O-linked glycans do interact with GpIb, but do so in
a coordinated manner. In addition, the presence of the glycans
prevents GpIb from binding to alternative sites in the VWF
protein, which only come available when deleting these glycans.
Deletion of one or two glycans from each of the clusters would be
insufficient in such case to allow GpIb access to this alternative
interactive region. Only the deletion of additional glycans relieves
this limitation, thereby restoring VWF-GpIb interactions.
Role of VWF O-Glycosylations
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37508Irrespective of the underlying mechanism, we would like to
emphasize that such compensatory mechanisms are not un-
precedented. They have for instance been described in perspective
of protein mutations. One example hereof have been described by
Plaimauer and colleagues, who demonstrated that the detrimental
effect of the Arg1336 to Trp mutation on ADAMTS13 bio-
synthesis is modulated by accompanying polymorphisms in this
protein [32]. But also mutations affecting glycosylation sites have
been reported in this regard. First, deletion of a single O-linked
glycan (T17A) in the activation peptide of coagulation factor X
increases the KM value for the activation by the tenase complex
complex 8-fold [33]. In contrast, such effect is not seen upon
deletion of the adjacent O-glycan (T29A). Moreover, deletion of
both O-glycans results in normal KM values as well, suggesting that
deletion of both O-glycans relieves the detrimental effect of
deletion of T17 alone. A second example relates to the N-glycans
of the HIV-1 gp120 envelope protein [34], which were studied in
relation to their role in HIV-1 replication. The replication
constant k of wt-gp120 was calculated to be 2.961, and mutation
of N186Q severely reduced the replication capacity of the virus
(k=0.196). However, the deletion of an additional glycan (N136 or
N141) restored the replication capacity of the virus (k=2.991 and
2.940, respectively) [34]. Of course, this does not mean that
additional deletion of glycans structures always result in compen-
sation. Nevertheless, these data show that it is difficult to predict
how single and multiple deletions of glycan sites affect the function
of glycosylated proteins.
Taken together, our study has evaluated for the first time the
contribution of O-linked glycans to the VWF life cycle. No gross
abnormalities with regard to biosynthesis and multimerization are
observed when these carbohydrates are missing, suggesting that
they are dispensable for these processes. In contrast, a combined
mutation of the adjacent T1255/T1256 residues impairs both
VWF function and survival. The reduced survival is shared with
the variant in which all O-linked glycans are removed, whereas
impaired function is shared with the T1255A, T1256 and S1486
single mutants. These data indicate that only a limited number of
O-linked glycans are of relevance in the biology of VWF, which is
compatible with the notion that so far no mutation affecting O-
glycosylation sites has been reported to lead to von Willebrand
disease. Finally, studying a VWF variant produced in vitro in an
O-linked glycosylation blocking environment may not be pre-
dictive of the individual effect of each O-glycosylation site since we
show here that specific sites may have more impact when affected
alone that in combination with other sites.
Author Contributions
Conceived and designed the experiments: MB PJL ODC CVD. Performed
the experiments: IB JR PL MB CC CVD MK. Analyzed the data: IB PL
PJL ODC CVD. Wrote the paper: IB PJL CVD.
Referneces
1. Sakariassen KS, Bolhuis PA, Sixma JJ (1979) Human blood platelet adhesion to
artery subendothelium is mediated by factor VIII-Von Willebrand factor bound
to the subendothelium. Nature 279: 636–638.
2. Weiss HJ, Sussman, II, Hoyer LW (1977) Stabilization of factor VIII in plasma
by the von Willebrand factor. Studies on posttransfusion and dissociated factor
VIII and in patients with von Willebrand’s disease. J Clin Invest 60: 390–404.
3. Ruggeri ZM (2003) Von Willebrand factor. Curr Opin Hematol 10: 142–149.
4. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, et al. (1986) Amino acid
sequence of human von Willebrand factor. Biochemistry 25: 3171–3184.
5. Rademacher TW, Parekh RB, Dwek RA (1988) Glycobiology. Annu Rev
Biochem 57: 785–838.
6. Varki A (1993) Biological roles of oligosaccharides: all of the theories are correct.
Glycobiology 3: 97–130.
7. Varki A, Freeze HH, Manzi AE (2009) Overview of glycoconjugate analysis.
Curr Protoc Protein Sci Chapter 12: Unit 12 11 12 11 11–18.
8. Wagner DD, Mayadas T, Marder VJ (1986) Initial glycosylation and acidic pH
in the Golgi apparatus are required for multimerization of von Willebrand
factor. J Cell Biol 102: 1320–1324.
9. McKinnon TA, Goode EC, Birdsey GM, Nowak AA, Chan AC, et al. (2010)
Specific N-linked glycosylation sites modulate synthesis and secretion of von
Willebrand factor. Blood 116: 640–648.
10. Davies JA, Collins PW, Hathaway LS, Bowen DJ (2008) von Willebrand factor:
evidence for variable clearance in vivo according to Y/C1584 phenotype and
ABO blood group. J Thromb Haemost 6: 97–103.
11. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA (2008) N-
linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood
111: 3042–3049.
12. Canis K, McKinnon TA, Nowak A, Panico M, Morris HR, et al. (2010) The
plasma von Willebrand factor O-glycome comprises a surprising variety of
structures including ABH antigens and disialosyl motifs. J Thromb Haemost 8:
137–145.
13. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, et al.
(2007) Variations in glycosylation of von Willebrand factor with O-linked
sialylated T antigen are associated with its plasma levels. Blood 109: 2430–2437.
14. Carew JA, Quinn SM, Stoddart JH, Lynch DC (1992) O-linked carbohydrate of
recombinant von Willebrand factor influences ristocetin-induced binding to
platelet glycoprotein 1b. J Clin Invest 90: 2258–2267.
15. Schulte am Esch J 2nd, Robson SC, Knoefel WT, Eisenberger CF, Peiper M, et
al. (2005) Impact of O-linked glycosylation of the VWF-A1-domain flanking
regions on platelet interaction. Br J Haematol 128: 82–90.
16. Julenius K, Molgaard A, Gupta R, Brunak S (2005) Prediction, conservation
analysis, and structural characterization of mammalian mucin-type O-
glycosylation sites. Glycobiology 15: 153–164.
17. Rayes J, Hollestelle MJ, Legendre P, Marx I, de Groot PG, et al. (2010)
Mutation and ADAMTS13-dependent modulation of disease severity in a mouse
model for von Willebrand disease type 2B. Blood 115: 4870–4877.
18. Palmiter RD, Behringer RR, Quaife CJ, Maxwell F, Maxwell IH, et al. (1987)
Cell lineage ablation in transgenic mice by cell-specific expression of a toxin
gene. Cell 50: 435–443.
19. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, et al. (2004) An
experimental model to study the in vivo survival of von Willebrand factor. Basic
aspects and application to the R1205H mutation. J Biol Chem 279:
12102–12109.
20. Mohlke KL, Purkayastha AA, Westrick RJ, Smith PL, Petryniak B, et al. (1999)
Mvwf, a dominant modifier of murine von Willebrand factor, results from
altered lineage-specific expression of a glycosyltransferase. Cell 96: 111–120.
21. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, et al. (1999) Estimation
of the von Willebrand factor-cleaving protease in plasma using monoclonal
antibodies to vWF. Thromb Haemost 82: 1382–1385.
22. Kauskot A, Adam F, Mazharian A, Ajzenberg N, Berrou E, et al. (2007)
Involvement of the mitogen-activated protein kinase c-Jun NH2-terminal kinase
1 in thrombus formation. J Biol Chem 282: 31990–31999.
23. Samor B, Michalski JC, Mazurier C, Goudemand M, De Waard P, et al. (1989)
Primary structure of the major O-glycosidically linked carbohydrate unit of
human von Willebrand factor. Glycoconj J 6: 263–270.
24. Marx I, Christophe OD, Lenting PJ, Rupin A, Vallez MO, et al. (2008) Altered
thrombus formation in von Willebrand factor-deficient mice expressing von
Willebrand factor variants with defective binding to collagen or GPIIbIIIa.
Blood 112: 603–609.
25. Marx I, Lenting PJ, Adler T, Pendu R, Christophe OD, et al. (2008) Correction
of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed
von Willebrand factor mutants. Arterioscler Thromb Vasc Biol 28: 419–424.
26. Chitta MS, Duhe RJ, Kermode JC (2007) Cloning of the cDNA for murine von
Willebrand factor and identification of orthologous genes reveals the extent of
conservation among diverse species. Platelets 18: 182–198.
27. Stoddart JH Jr., Andersen J, Lynch DC (1996) Clearance of normal and type 2A
von Willebrand factor in the rat. Blood 88: 1692–1699.
28. Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, et al. (2009)
Development of a plasma- and albumin-free recombinant von Willebrand
factor. Hamostaseologie 29 Suppl 1: S32–38.
29. Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, et al. (2006)
Shielding of the A1 domain by the D’D3 domains of von Willebrand factor
modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem 281:
4699–4707.
30. Martin C, Morales LD, Cruz MA (2007) Purified A2 domain of von Willebrand
factor binds to the active conformation of von Willebrand factor and blocks the
interaction with platelet glycoprotein Ibalpha. J Thromb Haemost 5:
1363–1370.
31. Cruz MA, Handin RI, Wise RJ (1993) The interaction of the von Willebrand
factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation
and disulfide bonding in a monomeric recombinant A1 domain protein. J Biol
Chem 268: 21238–21245.
Role of VWF O-Glycosylations
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e3750832. Plaimauer B, Fuhrmann J, Mohr G, Wernhart W, Bruno K, et al. (2006)
Modulation of ADAMTS13 secretion and specific activity by a combination of
common amino acid polymorphisms and a missense mutation. Blood 107:
118–125.
33. Yang L, Manithody C, Rezaie AR (2009) Functional role of O-linked and N-
linked glycosylation sites present on the activation peptide of factor X. J Thromb
Haemost 7: 1696–1702.
34. Auwerx J, Francois KO, Covens K, Van Laethem K, Balzarini J (2008) Glycan
deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity,
sensitize the mutant virus strains to carbohydrate-binding agents and represent
a specific target for therapeutic intervention. Virology 382: 10–19.
Role of VWF O-Glycosylations
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37508